25 patents currently held

1 more in force is now held by another company

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Nov 2030. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Nov 2030

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036 2037 2038 2039 2040 2041 2042204320442045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Compositions and Methods for Intravenous Administration of 2-Bromo-1-(3,3-Dinitroazetidin-1-YL)ETHANONE US 11,576,895

Cited by 13 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2038.

Ends Aug 2038 · High confidence Also notable

METHODS AND COMPOSITIONS UTILIZING RRx-001 COMBINATION THERAPY FOR RADIOPROTECTION US 11,510,901

Cited by 13 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2039.

Ends May 2039 · High confidence Also notable

Immunomodulatory Oncolytic Adenoviral Vectors, and Methods of Production and Use Thereof for Treatment of Cancer US 10,232,053

Cited by 21 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2037.

Ends Dec 2037 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Nov 30, 2026
The maintenance fee for Methods and Compositions Comprising a Nitrite-Reductase Promoter for Treatment of Medical Disorders and Preservation of Blood Products (US 11,660,286) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
2 fees due Jan 9 to 18, 2027 · next Jan 9
2 fees due Mar 5 to 22, 2027 · next Mar 5
1 fee due Jun 5, 2027
The maintenance fee for Human IL-10 Receptor Alpha Fusion Proteins (US 11,834,492) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
1 fee due Jul 28, 2027
The maintenance fee for Treatment of Gliomas Using Organonitro Compound Combination Therapy (US 10,543,208) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 5 largest of its 18 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Method for Producing Recombinant Oncolytic Adenovirus with Modified E1A Cancer-Specific Promoter	2 in force	to Jul 2040
METHODS AND COMPOSITIONS UTILIZING RRx-001 COMBINATION THERAPY FOR RADIOPROTECTION	2 in force	to May 2039
Compositions and Methods for Intravenous Administration of 2-Bromo-1-(3,3-Dinitroazetidin-1-YL)ETHANONE	2 in force	to Aug 2038
Immunomodulatory Fusion Proteins	2 in force	to Sep 2037
Treatment of Brain Metastases Using Organonitro Compound Combination Therapy	2 in force	to Apr 2037

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 9,511,016	Topical Composition for Treating Pain In force Term ends Nov 1, 2030 · High confidence	In force	Term ends Nov 1, 2030	High confidence
US 9,139,519	Organonitro Thioether Compounds and Medical Uses Thereof In force Term ends May 18, 2032 · High confidence	In force	Term ends May 18, 2032	High confidence
US 9,468,625	Organonitro Thioether Compounds and Medical Uses Thereof In force Term ends May 18, 2032 · High confidence	In force	Term ends May 18, 2032	High confidence
US 11,660,286	Methods and Compositions Comprising a Nitrite-Reductase Promoter for Treatment of Medical Disorders and Preservation of Blood Products In force Term ends Oct 5, 2032 · High confidence	In force	Term ends Oct 5, 2032	High confidence
US 11,160,784	Treatment of Brain Metastases Using Organonitro Compound Combination Therapy In force Term ends Oct 20, 2036 · High confidence	In force	Term ends Oct 20, 2036	High confidence
US 10,543,208	Treatment of Gliomas Using Organonitro Compound Combination Therapy In force Term ends Oct 28, 2036 · High confidence	In force	Term ends Oct 28, 2036	High confidence
US 11,701,351	Treatment of Gliomas Using Organonitro Compound Combination Therapy In force Term ends Oct 28, 2036 · High confidence	In force	Term ends Oct 28, 2036	High confidence
US 10,342,778	Treatment of Brain Metastases Using Organonitro Compound Combination Therapy In force Term ends Apr 1, 2037 · High confidence	In force	Term ends Apr 1, 2037	High confidence
US 12,357,607	Compositions and Methods for Intravenous Administration of 2-Bromo-1-(3,3-Dinitroazetidin-1-YL)ETHANONE In force Term ends Jul 3, 2037 · High confidence	In force	Term ends Jul 3, 2037	High confidence
US 10,906,957	Immunomodulatory Fusion Proteins In force Term ends Sep 27, 2037 · High confidence	In force	Term ends Sep 27, 2037	High confidence

10 of 25 patents shown.

Pro members see all 25.

Pro members: see all 25 patents

Also on record, not counted in the 25: 1 patent in force now held by others · 8 patents ended · 11 applications pending · 25 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Epicentrx, Inc.